
    
      This trial openly recruited 50 patients into the group and were given CAR-T treatment.
      Patients participating in clinical trials will be tested and evaluated in terms of treatment
      safety, efficacy, and response duration. As assessed by clinicians, adult B-ALL patients who
      meet the enrollment criteria, after adequate communication, the patient or family members
      voluntarily join the clinical study, and are willing to bridge allogeneic hematopoiesis
      within 3 months after enrollment using CAR-T therapyã€‚
    
  